These pressures matter disproportionately in deferrable medtech segments, where rising costs are difficult to pass through without affecting demand, especially in price-sensitive markets.<\/p>\n
![\"External](\"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-content\/uploads\/sites\/4\/2026\/06\/Slide1.jpg\")
<\/p>\n
Why growth expectations are moderated in deferrable treatment markets<\/h3>\n
In medtech markets with deferrable treatments such as medical aesthetics, early expectations for a sharp post-2025 rebound have increasingly given way to more measured near-term outlooks. This is not driven by weakening long-term demand. Escalating energy costs, freight inflation, and logistics disruption have added friction to an environment already shaped by affordability concerns.<\/p>\n
In cash-pay and elective settings, these pressures influence both provider purchasing behavior and patient decision-making more immediately than in medically necessary or reimbursed treatment areas.<\/p>\n
Current signals instead suggest:<\/p>\n
- \n
- Muted near-term growth in deferrable treatments<\/li>\n
- Expected recovery in these areas, but at a more gradual pace<\/li>\n
- Stabilization of volumes before re\u2011acceleration<\/li>\n<\/ul>\n
![\"Key](\"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-content\/uploads\/sites\/4\/2026\/06\/Slide2.jpg\")
<\/p>\nBeyond aesthetics: implications for other medtech markets<\/h3>\n
Currently, less deferrable and reimbursement-driven device markets remain structurally more insulated from these short-term demand adjustments.<\/p>\n
While aesthetics has served as an early indicator for more deferrable treatment areas, similar dynamics could apply across other medtech segments, including parts of orthopedics, dental, and other markets centered on more elective treatments.<\/p>\n
The broader takeaway for 2026 is clear: elective medtech markets remain resilient, but companies must adapt how they respond to evolving external pressures.<\/p>\n
Organizations that recognize these changes early, adjust expectations thoughtfully, and identify which markets are most exposed to external shocks will be better positioned to navigate current market conditions.<\/p>\n
Turning insight into action in a changing medtech landscape<\/h3>\n
As economic and geopolitical pressures reshape elective medtech markets, decision\u2011makers need timely visibility into where demand is shifting, how pricing pressure is evolving, and which segments are most exposed to external shocks.<\/p>\n
Clarivate\u2019s Medtech intelligence solutions help organizations:<\/p>\n
- \n
- Track procedure volumes and utilization shifts across care settings<\/strong>
\n\u2192 EU Procedure Finder<\/em><\/a> | DRG Commercial Analytics 360<\/em><\/a><\/li>\n- Understand pricing pressure and demand sensitivity in elective segments<\/strong>
\n\u2192 PriceTrack<\/em><\/a><\/li>\n- Benchmark market trends, growth outlooks, and competitive dynamics<\/strong>
\n\u2192 Medtech 360<\/em><\/a><\/li>\n<\/ul>\n - Understand pricing pressure and demand sensitivity in elective segments<\/strong>
- Track procedure volumes and utilization shifts across care settings<\/strong>